Dose accumulation for personalized stereotactic MR-guided adaptive radiation therapy in prostate cancer.

Abstract

Adaptive MR-guided radiotherapy (MRgRT) is an innovative approach for delivering stereotactic body radiotherapy (SBRT) in prostate cancer (PC). Despite the increased clinical use of SBRT for PC, there is limited data on the relation between the actual delivered dose and toxicity. We aimed to identify dose parameters based on the total accumulated delivered bladder dose (DOSE_ACC^TX). Furthermore, for future personalization, we studied whether prospective accumulation of the first 3 of 5 fractions (DOSE_ACC^3FR) could be used as a representative of DOSE_ACC^TX. We deployed a recently validated deformable image registration-based dose accumulation strategy to reconstruct DOSE_ACC^TX and DOSE_ACC^3FR in 101 PC patients treated with stereotactic MRgRT. IPSS scores at baseline, end of MRgRT, at 6 and 12 weeks after treatment were analyzed to identify a clinically relevant increase of acute urinary symptoms. A receiver operator characteristic curve analysis was used to investigate the correlation of an increase in IPSS and bladder DOSE_ACC^TX (range V₅-V_{36.25 Gy,} D_1cc, D_5cc) and DOSE_ACC^3FR (range V₆-V_{21.8 Gy,} D_1cc, D_5cc) parameters. A clinically relevant increase in IPSS in the three months following MRgRT was observed in 25 patients. The V_20Gy-32Gy from DOSE_ACC^TX and V_15Gy-18Gy from DOSE_ACC^3FR showed good correlation with IPSS increase with area under the curve (AUC) values ranging from 0.71 to 0.75. In contrast, baseline dosimetry showed a poor correlation with AUC values between 0.53 and 0.62. DOSE_ACC^TX was superior to baseline dosimetry in predicting acute urinary symptoms. Because DOSE_ACC^3FR also showed good correlation, this can potentially be used to optimize MRgRT for the remaining fractions.